The completion of the human genome project and additional ongoing efforts such as the international haplotype map (HapMap) project have promoted the exponential development of tools to investigate global genomic profiles at the DNA and transcript levels. Rapidly evolving technology now allows the interrogation of 1.8 million genetic markers (including almost one million single-nucleotide polymorphisms [SNPs]) on a single-array platform to study genome-wide variations in copy number and loss of heterozygosity. Likewise, more than 50,000 gene transcripts can be probed on a single microarray chip. This article highlights the use of these tools in childhood acute lymphoblastic leukemia (ALL) in order to better understand the mechanisms of leukemogenesis, develop new prognostic markers, and identify potential therapeutic targets. The integration of genome-wide studies of structural changes in DNA, expression levels of transcripts, microRNA profiles, epigenetics (including DNA methylation and histone acetylation), and re-sequencing efforts can provide further insight to enhance the management of this common childhood malignancy.
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Prognostication
Risk-adapted therapy for ALL is the norm in developed countries, wherein therapy is tailored according to the predicted risk for relapse. 1 Between one and 10 years of age, a leukocyte count <50,000/µl at presentation and genetic features of leukemic cells such as hyperdiploidy >50 chromosomes and t (12;21) [ETV6-RUNX1] are favorable prognostic indicators, whereas hypodiploidy, t (9;22) 
[BCR-ABL]
and MLL gene re-arrangements are unfavorable features. 1 Also, the rapidity of blast clearance during remission-induction treatment as measured by minimal residual disease (MRD) with flow cytometry or polymerase chain reaction is a sensitive prognostic indicator. However, many relapses still occur in patients without known adverse characteristics at presentation, and efforts are focused on identifying additional attributes in both the host and the tumor that can improve the accuracy of current risk-stratification schemes.
After modern high-density genomic tools became accessible, investigators embarked on a search for a gene-expression signature of diagnostic leukemic blasts that could predict outcome. The Affymetrix U133Plus 2.0 platform was used to identify a 48-gene expression signature predicting outcome in a Children's Oncology Group (COG) study of patients treated on a high-risk protocol (COG1961). 2 This signature was validated in three independent cohorts treated by different study groups, but was unable to provide additional benefit for prognostication when age, leukocyte count, and cytogenetics were included in a multivariate analysis. ALL is a heterogeneous disease comprising various genetic subtypes with prognostic implications, thus making it difficult to identify a universal signature for response. For example, Yeoh et al. identified a
prognostic signature in two subtypes of ALL (T-cell and hyperdiploid), 3 although these findings require further validation. The detailed study of genetic lesions and pathways that render chemoresistance within individual known subtypes and the identification of additional subtypes of ALL with prognostic relevance may be more beneficial than identifying a universal signature.
Identification of Novel Biological Subtypes Associated with Outcome
It is well-established that gene-expression patterns can be used to accurately classify various subtypes of ALL, as these patterns are influenced by pivotal genetic lesions. 3 However, approximately 25% of cases of childhood ALL have no known genetic characteristics. 4 Unique biological subgroups that are characterized by similarities in gene-expression profiles have been identified in such cases. 3 
BCR-ABL1-like Acute Lymphoblastic Leukemia
In a recent study by den Boer et al. 5 therapeutic protocols differ, pooling of data generated by all study groups may strengthen the evidence of the existence of high-risk subsets.
Early T-cell Precursor Acute Lymphoblastic Leukemia
Prognostic features for T-cell ALL have not been as well characterized as for B-lineage disease, but with modern intensive therapy the outcome for T-cell ALL has approached 80%. 
Prediction of Early Response to Therapy
The ability to monitor MRD has been one of the most significant contributions to the management of childhood ALL this decade and is the most powerful predictor of overall outcome in contemporary ALL protocols. 14, 15 This sensitive measurement of early treatment response is prognostic for overall DFS after initial diagnosis, post-relapse, and before stem cell transplantation. [14] [15] [16] [17] Subsets of patients at high risk for treatment failure can be identified relatively early, and therapy can be intensified for patients without satisfactory reduction in disease burden at pre-defined time-points, usually within the first few weeks of initiating therapy. Although MRD is an excellent surrogate marker for treatment response, the precise factors contributing to early disease regression are not completely understood. Genome-wide studies have attempted to tumors from glucocorticoid-induced apoptosis in vitro, 22 and its high expression in leukemic cells has been previously shown to be related to risk for CNS involvement in childhood ALL. 23 
Prediction of Drug Sensitivity
Intrinsic resistance to single or multiple chemotherapeutic agents is a significant hindrance to cure, and the molecular determinants of drug resistance have been explored extensively. In vitro drug sensitivity of primary leukemic cells to commonly used antileukemic agents (prednisolone, vincristine, asparaginase, and daunorubicin) has been correlated to their global gene-expression profiles. 24 There was minimal overlap between the genes included in the resistance profiles of the four individual drugs, but a combined gene-expression score was significantly associated with outcome. Subsequently, a multidrug resistance phenotype was employed to compute a cross-resistance score that identified patients at high risk for relapse. 25 The five-year DFS for cross-resistant patients was 53±10% versus 91±5% for crosssensitive patients. In addition to identifying patients at high risk for treatment failure, the genes and pathways implicated in these studies may provide rational approaches to bypassing drug-specific and multidrug resistance and eventually to tailoring therapy on the basis of resistance patterns to various agents.
Prediction of Adverse Events
The best characterized and clinically valuable example in the pharmacogenetics of ALL is the influence of polymorphisms in the thiopurine S-methyltransferase (TPMT) gene on hematopoietic toxicity secondary to thiopurines commonly used in ALL. 26 Additional candidate-gene approaches have shown that polymorphisms in the vitamin D receptor (VDR) folkI site TYMS27 and the PAI 1 28 are associated with the risk for osteonecrosis and polymorphisms in eight genes associated with hypertension secondary to steroid treatment in ALL. 29 With the current availability of genome-wide technologies, adverse-event phenotypes are being correlated to individual genotypes for further individualization of therapy.
Secondary leukemia, particularly secondary acute myeloid leukemia (AML), is an uncommon but devastating adverse event after patients are exposed to chemotherapeutic agents, such as topoisomerase II inhibitors and alkylating agents. These agents must be avoided as much as possible in patients at risk for developing secondary leukemia. To identify at-risk patients, Hartford et al. used genomic tools to study copy number and gene-expression changes in samples from children with ALL exposed to etoposide. They found that 309 germline SNPs differed significantly between patients with ALL who developed secondary leukemia (cases) and those treated on similar protocols but who did not develop secondary leukemia (controls). 30 In addition to these inherited variations, 11q23 translocations and multiple cryptic regions of loss of heterozygosity were acquired in the blasts of the secondary leukemia cells. These data were complemented by profiles of genes differentially expressed in diagnostic blasts of cases and controls; pathways related to focal adhesion and Wnt signaling were among those that were affected and were suggested to play a role in the pathogenesis of secondary leukemia.
Biological Insights
The recognition of specific molecular lesions and critical oncogenic pathways paves the way for novel targeted approaches to therapy, such as the development of tyrosine kinase inhibitors for BCR-ABL1-positive hematological malignancies. The study of the global genomic portrait of ALL can provide further insights into the pathways that play a role in leukemogenesis and possibly chemoresistance. 
Co-operative Lesions

Relapsed Acute Lymphoblastic Leukemia
Approximately 10-20% of children with ALL ultimately relapse, and their outcome is poor despite extremely intensive therapy, including stem cell transplantion. Timing and site of relapse are prognostic of outcome; early medullary relapse portends the worst outcome.
Matched samples from the same patient at diagnosis, remission, and relapse offer the opportunity to study the pathways leading to relapse and to identify novel therapeutic targets. A global gene-expression study of 35 patients at diagnosis and relapse suggested that pathways leading to early and late relapse may differ. 31 Samples from early relapse demonstrated gene-expression patterns that were more similar to their diagnostic counterparts than samples at late relapse, indicating the emergence of a related resistant clone. Early relapse was also characterized by a proliferative signature, with upregulation of genes involved in cell-cycle progression, DNA repair, and antiapoptosis/cell survival.
Two recent studies of high-resolution copy-number profiling of matched samples have demonstrated clonal evolution from diagnosis to relapse. 32, 33 In these studies, multiple novel copy number losses or gains were acquired at the time of relapse. The frequency of deletions in CDKN2A, IKZF1, and EBF1 was higher in the relapsed cohort 32 than in previously published cohorts at initial diagnosis, 8 suggesting a role in resistance. Two patients showed relapse-specific focal deletions at the locus for MSH6. 32 MSH6 is a component of the mismatch repair machinery and has been implicated in resistance to thiopurines, drugs commonly used for prolonged periods in ALL regimens.
Backtracking studies have revealed that in most cases the clone responsible for relapse is present as a minor subclone at initial diagnosis. 33 The relapse clone either evolves from an ancestral pre-leukemic clone or is clonally related to the diagnostic clone.
Interestingly, there is a paucity of common shared lesions specific to relapse, but cell-cycle regulation and B-cell development pathways have been frequently targeted at relapse. 37 Microarray studies have also revealed low expression of the tumor suppressor FHIT in MLL-re-arranged ALL. 38 FHIT is silenced by methylation and its function can be restored by using demethylating agent, such as decitabine. 38 Gene-expression profiles of paired leukemic samples from patients at initial diagnosis and at relapse have identified multiple genes upregulated at the time of relapse that may contribute to the poor response to retrieval therapy. 31 One such target is BIRC5, also known as survivin, an inhibitor of apoptosis that is highly expressed on relapsed ALL and other aggressive tumors, such as neuroblastoma. 39 Additional pre-clinical experiments and phase I studies of small-molecule inhibitors and antisense oligonucleotides are ongoing. 40, 41 The selective expression of survivin in tumor tissue makes it an attractive therapeutic target.
Identification of Therapeutic Targets
Conclusions
Although 80-90% of children with ALL can be cured with current multiagent therapy, it may be possible to reduce the intensity of therapy and the subsequent short-and long-term side effects in a subset of patients. On the other hand, the prognosis for children who relapse is extremely poor and innovative strategies to prevent and treat relapse are urgently needed.
High-throughput genomic technologies promise to uncover multiple dimensions of the cancer phenotype. In childhood ALL, novel genetic subtypes have been identified that not only are valuable for outcome prediction but also provide numerous candidate genes that are being examined further to decipher complex pathways underlying leukemia 
